Michail Ignatiadis, MD, PhD, is a medical oncologist specializing in breast cancer at the Institut Jules Bordet (IJB), Hôpital Universitaire de Bruxelles (H.U.B.) in Brussels, Belgium. He serves as the Director of the Breast Medical Oncology Clinic & Program and is a Professor of Medical Oncology. Since October 2016, he has been a member of the Executive and Research Boards of IJB and leads the Academic Trials Promoting Team (ATPT).

Since January 2021, Prof. Ignatiadis has chaired the Breast Cancer Group of the European Organisation for Research and Treatment of Cancer (EORTC). Previously, from June 2018 to January 2021, he was a member of the EORTC Board of Directors, serving as Chair of the Clinical Research Division.

Prof. Ignatiadis has played a key role in numerous investigator-initiated trials (IITs) sponsored by IJB, contributing at various stages of development. He has also served on Independent Data Monitoring Committees for international trials and has been the study chair for multiple IITs and industry-sponsored trials. His expertise in immunotherapy and blood-based biomarkers is widely recognized at the international level.

He has authored over 100 publications in peer-reviewed journals, including high-impact journals such as JAMA, Journal of Clinical Oncology, Nature Reviews Clinical Oncology, Annals of Oncology, Lancet Oncology, JAMA Oncology, and Journal of the National Cancer Institute.

With more than two decades of experience in clinical research, leadership, and academia, Prof. Ignatiadis is a seasoned expert in the field of medical oncology.